These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 26167067)

  • 1. Personalized targeted therapy for esophageal squamous cell carcinoma.
    Kang X; Chen K; Li Y; Li J; D'Amico TA; Chen X
    World J Gastroenterol; 2015 Jul; 21(25):7648-58. PubMed ID: 26167067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.
    Saito T; Mitomi H; Yao T
    Int J Clin Exp Pathol; 2015; 8(3):2267-73. PubMed ID: 26045734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
    Sasaki Y; Tamura M; Koyama R; Nakagaki T; Adachi Y; Tokino T
    World J Gastroenterol; 2016 Feb; 22(7):2284-93. PubMed ID: 26900290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
    Yang JW; Choi YL
    Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.
    Harwood CA; Proby CM; Inman GJ; Leigh IM
    Acta Derm Venereol; 2016 Jan; 96(1):3-16. PubMed ID: 26084328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.
    Liu Y; Xiong Z; Beasley A; D'Amico T; Chen XL
    Ann N Y Acad Sci; 2016 Oct; 1381(1):66-73. PubMed ID: 27399176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel candidate genes may be possible predisposing factors revealed by whole exome sequencing in familial esophageal squamous cell carcinoma.
    Forouzanfar N; Baranova A; Milanizadeh S; Heravi-Moussavi A; Jebelli A; Abbaszadegan MR
    Tumour Biol; 2017 May; 39(5):1010428317699115. PubMed ID: 28459198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
    Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma.
    Ohashi S; Miyamoto S; Kikuchi O; Goto T; Amanuma Y; Muto M
    Gastroenterology; 2015 Dec; 149(7):1700-15. PubMed ID: 26376349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in esophageal cancer.
    Zhang L; Ma J; Han Y; Liu J; Zhou W; Hong L; Fan D
    Expert Rev Gastroenterol Hepatol; 2016; 10(5):595-604. PubMed ID: 26895097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells.
    Hsu HS; Lin MH; Jang YH; Kuo TT; Liu CC; Cheng TH
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):378-85. PubMed ID: 25439783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
    Seim NB; Kang SY; Bhandari M; Jones RG; Teknos TN
    Ann Otol Rhinol Laryngol; 2017 Apr; 126(4):334-339. PubMed ID: 28061634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A precision, personalized approach to the management of bladder cancer.
    Apolo AB; Burger M
    Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
    [No Abstract]   [Full Text] [Related]  

  • 18. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
    Sugase T; Takahashi T; Serada S; Nakatsuka R; Fujimoto M; Ohkawara T; Hara H; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
    Int J Cancer; 2017 Jun; 140(11):2608-2621. PubMed ID: 28233302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of liver cancer and personalized therapy.
    Li L; Wang H
    Cancer Lett; 2016 Sep; 379(2):191-7. PubMed ID: 26213370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.